Grab A 5% Yield With GlaxoSmithKline plc, Standard Life Plc And Tate & Lyle PLC

These 3 stocks offer stunning income prospects: GlaxoSmithKline plc (LON: GSK), Standard Life Plc (LON: SL) and Tate & Lyle PLC (LON: TATE).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

With interest rates likely to remain low over the coming years, the ability to achieve a 5% yield on high quality companies is highly enticing. That’s especially the case when the prospects for a number of those stocks are upbeat and also because their future dividend growth could easily beat inflation.

Positive outlook

For example, Standard Life (LSE: SL) currently yields 5.4% and with the asset manager having a strong track record of increasing dividends per share, the outlook for future dividend growth is very positive. Shareholder payouts have risen by around 7.3% per annum during the last five years, which is considerably higher than the rate of inflation during that time. And with dividends being covered 1.4 times by profit, there’s clear scope for further rises moving forward.

In fact, Standard Life’s bottom line is expected to increase by 9% in 2017 and this should allow it to raise dividends by around 7.7%. This could act as a positive catalyst on the company’s share price and allow it to reverse the 35% fall over the last year. With Standard Life trading on a price-to-earnings growth (PEG) ratio of 1.3, it seems to offer excellent value for money, too.

Should you invest £1,000 in Centamin right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Centamin made the list?

See the 6 stocks

Sweet pick

Also having a yield above 5% is Tate & Lyle (LSE: TATE). Although the last few years have been challenging for the business due to a variety of factors, including commodity pricing pressure and increased competition for the company’s products, it’s expected to turn things around in 2017 and 2018. In fact, its bottom line is forecast to rise by 10% in the next financial year, and by a further 5% in the year following that.

This turnaround could act as a positive catalyst not only on Tate & Lyle’s share price, but also on its dividend payments. With the company’s shareholder payouts being covered 1.3 times by profit, there’s scope to increase dividends at a similar pace to profit growth over the medium-to-long term. While further challenges could lie ahead, Tate & Lyle now seems to have a better organised supply chain through which to move forward, while its price-to-earnings (P/E) ratio of 15.3 indicates that there remains substantial upward rerating potential.

Non-cyclical star

Meanwhile, GlaxoSmithKline (LSE: GSK) continues to be one of the highest yielding shares in the FTSE 100. Its yield stands at 5.7% and while dividend growth is expected to be lacking over the next couple of years, GlaxoSmithKline has the potential to raise dividends at a rapid rate over the long term.

A key reason for that is the changes the company is making to its business model. It’s seeking to drive through over £1bn in cost savings in the next few years and this could help to improve profitability. Furthermore, GlaxoSmithKline’s dividend growth should be positively impacted by its impressive and diversified pipeline of new drugs that have the potential to reinvigorate its bottom line following a period of rather lacklustre growth.

As well as a top-notch yield and upbeat dividend growth prospects, GlaxoSmithKline remains a relatively defensive option. It has a beta of 0.9, which indicates that its shares should be less volatile than the wider index, while its lack of cyclicality means that its shares could rise even if the macroeconomic outlook remains uncertain.

AI Revolution Awaits: Uncover Top Stock Picks for Massive Potential Gains!

Buckle up because we're about to dive headfirst into the electrifying world of AI.

Imagine this: you make a single savvy investment in some cutting-edge technology, then kick back and watch as it revolutionises entire industries and potentially even lines your pockets.

If the mere thought of riding this AI wave excites you and the prospect of massive potential returns gets your pulse racing, then you’ve got to check out this Motley Fool Share Advisor report – 'AI Front Runners: 3 Surprising Stocks Riding The AI Wave’!

And here’s the kicker – we’re giving you an exclusive peek at ONE of these top AI stock picks, absolutely free! How’s that for a bit of brilliance?

Get your free AI stock pick

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of GlaxoSmithKline, Standard Life, and Tate & Lyle. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Two employees sat at desk welcoming customer to a Tesla car showroom
Investing Articles

Could Tesla stock be a brilliant bargain in plain sight?

Christopher Ruane sees some things to like about Tesla, but as its vehicle revenues have gone into sharp decline, is…

Read more »

British coins and bank notes scattered on a surface
Investing Articles

3 cheap FTSE 250 stocks with big dividends to consider buying right now

The FTSE 250's loaded with so many big dividend yields it's hard to know where to start. These three have…

Read more »

Rolls-Royce's Pearl 10X engine series
Investing Articles

Up 585%, could Rolls-Royce shares still go higher?

Christopher Ruane likes the Rolls-Royce business but is not so convinced by the value its current share price offers him.…

Read more »

Silhouette of a bull standing on top of a landscape with the sun setting behind it
Investing Articles

I reckon a bull market’s coming! Here’s what I’m buying for my Stocks and Shares ISA

Hoping to capitalise on what he believes is an undervalued UK stock market, our writer’s added more of this FTSE…

Read more »

piggy bank, searching with binoculars
Investing Articles

The UK stock market looks undervalued to me. Here’s 1 growth stock to consider for a SIPP

Our writer explains why he thinks the UK stock market’s currently in bargain territory, and identifies one share potentially worthy…

Read more »

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
Investing Articles

Meet the FTSE 100 stock I’ve been buying this week

Despite a strong week for the FTSE 100, one stock fell 7% in a day. And Stephen Wright took the…

Read more »

Businesswoman calculating finances in an office
Investing Articles

1 of my favourite growth stocks crashed 20% in a day this week. Here’s what I’m doing

Stephen Wright thinks the market’s overreacting to short-term growth challenges in one of his favourite UK stocks, creating a buying…

Read more »

Young female hand showing five fingers.
Investing Articles

Here’s a 5-stock high-yielding portfolio that could generate passive income of £1,500 a year

Those wanting to earn generous levels of passive income from their Stocks and Shares ISA could take a closer look…

Read more »